---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-023060"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:57:55.373889+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci reports Q1 net loss $22M, cash $161.5M; advances ABS-101 to IND-enabling studies

## Summary
- Q1 2024 revenue $0.9M (down from $1.3M YoY); net loss $22.0M vs $23.4M prior year.
- Cash, equivalents & short-term investments $161.5M as of Mar 31, 2024, up from $97.7M Dec 31, 2023; includes $86.4M gross from March offering.
- IND-enabling studies initiated for ABS-101 (anti-TL1A antibody) in Feb 2024; expects Phase 1 start early 2025, interim data H2 2025.
- Anticipates selecting development candidate for ABS-201 (dermatology) in H2 2024; ABS-301 (immuno-oncology) advancing.
- Expects to sign at least four drug creation partnerships in 2024; cash runway into H1 2027.

## SEC filing metadata
- accession: 0001628280-24-023060
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828024023060/0001628280-24-023060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828024023060/absc-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-023060
- JSON: https://secwatch.observer/filing/0001628280-24-023060.json
- Plain text: https://secwatch.observer/filing/0001628280-24-023060.txt

## Key facts
- Earnings Releases
  Absci Corp reported the quarter ended March 31, 2024 results: revenue $0.9 million, net income $22.0 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $0.9 million
  - Net income: $22.0 million
  - Result: reported results
  source text: Revenue was $0.9 million for the three months ended March 31, 2024 compared to $1.3 million for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672688/000162828024023060/0001628280-24-023060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.